Dx & Vx Co., Ltd. Logo

Dx & Vx Co., Ltd.

A bio-healthcare company specializing in diagnostics and mRNA vaccine development.

180400 | KO

Overview

Corporate Details

ISIN(s):
KR7180400004
LEI:
Country:
South Korea
Address:
서울특별시 금천구 디지털로 173, 금천구

Description

Dx & Vx Co., Ltd. is a bio-healthcare company specializing in diagnostics and vaccine development. Its diagnostics division offers molecular diagnostic solutions, genomics and bioinformatics services, and customized companion diagnostics (CDx), leveraging an AI-based genome analysis platform. The company's therapeutic pipeline is centered on an innovative mRNA vaccine platform designed for long-term storage at room temperature. Key development areas include vaccines for infectious diseases, immuno-therapeutic cancer vaccines, oral treatments for obesity, and therapies for eye conditions. Additionally, Dx & Vx provides contract development, manufacturing, and sales organization (CDMO/CSO) services and commercializes microbiome-based products and health supplements.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-12-04 00:00
의결권대리행사권유참고서류
Korean 38.1 KB
2024-12-04 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2024-11-14 00:00
분기보고서 (2024.09)
Korean 1.5 MB
2024-11-11 00:00
[기재정정]주요사항보고서(회사합병결정)
Korean 40.1 KB
2024-11-11 00:00
[기재정정]주요사항보고서(회사합병결정)
Korean 36.9 KB
2024-11-05 00:00
주주총회소집결의 (임시주주총회)
Korean 8.3 KB
2024-11-05 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.7 KB
2024-10-07 00:00
주식등의대량보유상황보고서(약식)
Korean 57.3 KB
2024-10-04 00:00
증권신고서(합병)
Korean 4.5 MB
2024-10-02 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.5 KB
2024-10-02 00:00
[첨부추가]주요사항보고서(회사합병결정)
Korean 34.3 KB
2024-09-27 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.5 KB
2024-09-25 00:00
전환사채(해외전환사채포함)발행후만기전사채취득 (제6회차)
Korean 9.0 KB
2024-09-24 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.3 KB
2024-09-24 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.3 KB

Automate Your Workflow. Get a real-time feed of all Dx & Vx Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dx & Vx Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Dx & Vx Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.